Engy Elkoury
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Engy Elkoury has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Muhammed Elhadi
College of Medicine, Korea University, Seoul, South Korea
3 shared publications - Munder Lateiresh
Faculty of Medicine Foča, University of East Sarajevo, Foča, Bosnia and Herzegovina
3 shared publications - Ayham Qatza
Faculty of Medicine Hama University Hama Syria
2 shared publications - Asmaa Yehia
Department of Neuroscience, Graduate School of Biomedical Sciences, Mayo Clinic College of Medicine, Phoenix, AZ 58054, USA
1 shared publication - Dakota Ortega
Preclinical Imaging Core, Arizona State University, Tempe, AZ 85257, USA
1 shared publication - Elisabeth de Castro Caparelli
Neuroimaging Research Branch, National Institute on Drug Abuse, National Institutes of Health, Baltimore, Maryland, USA
1 shared publication
Latest Publications
- Open Access
- 9 June 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Efficacy and safety of nasal mask compared to nasal cannula during procedural sedation in gastroscopy: a systematic review, meta-analysis, and trial sequential analysis
Hypoxemia is the most common adverse event during propofol-based procedural sedation for gastroscopy. Conventional nasal cannula oxygenation provides low flow rates, permitting room air entrainment and often proving insufficient. Nasal mask oxygenation delivers higher inspired oxygen concentrations, potentially enhancing respiratory safety during sedation. This study compared the efficacy and safety of nasal mask versus nasal cannula oxygen delivery during propofol-based procedural sedation for gastroscopy. Electronic databases/registries were systematically searched from inception to January 24, 2026, for randomized controlled trials (RCTs). Inclusion criteria encompassed adult patients undergoing propofol-based sedation for gastroscopy. The primary outcome was the incidence of hypoxemia. Secondary outcomes included severe hypoxemia, minimum oxygen saturation (SpO₂), need for airway or oxygenation interventions, procedure-related adverse events, and postoperative nausea and vomiting (PONV). Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Trial sequential analysis (TSA) assessed the sufficiency of the evidence. Risk of bias was evaluated using RoB 2, and certainty of evidence using GRADE. Five RCTs enrolled 1,267 patients, of whom 1,252 (98.8%) were included in the quantitative synthesis. Nasal mask oxygenation significantly reduced hypoxemia (RR 0.40, 95% CI 0.28 to 0.58, p < 0.0001) and severe hypoxemia (RR 0.39, 95% CI 0.22 to 0.67, p = 0.0007) compared with nasal cannula. Nasal masks also decreased the need for jaw thrust (RR 0.40, 95% CI 0.31 to 0.52) and mask-assisted ventilation (RR 0.16, 95% CI 0.05 to 0.46), while elevating minimum SpO₂ (MD 3.78, 95% CI 1.39 to 6.16). No significant differences emerged in coughing, hiccups, or PONV. Nasal mask oxygenation is associated with greater respiratory safety compared with nasal cannula oxygenation during propofol-sedated gastroscopy. This advantage manifests as reduced incidence of hypoxemia and fewer airway-related interventions, alongside a comparable overall safety profile. CRD420261291468.
- 9 June 2026
- Published by Springer Nature in BMC Anesthesiology
- Vol. 26 (1)
Open AccessEfficacy and safety of nasal mask compared to nasal cannula during procedural sedation in gastroscopy: a systematic review, meta-analysis, and trial sequential analysis
Hypoxemia is the most common adverse event during propofol-based procedural sedation for gastroscopy. Conventional nasal cannula oxygenation provides low flow rates, permitting room air entrainment and often proving insufficient. Nasal mask oxygenation delivers higher inspired oxygen concentrations, potentially enhancing respiratory safety during sedation. This study compared the efficacy and safety of nasal mask versus nasal cannula oxygen delivery during propofol-based procedural sedation for gastroscopy. Electronic databases/registries were systematically searched from inception to January 24, 2026, for randomized controlled trials (RCTs). Inclusion criteria encompassed adult patients undergoing propofol-based sedation for gastroscopy. The primary outcome was the incidence of hypoxemia. Secondary outcomes included severe hypoxemia, minimum oxygen saturation (SpO₂), need for airway or oxygenation interventions, procedure-related adverse events, and postoperative nausea and vomiting (PONV). Random-effects meta-analyses were performed using risk ratios (RRs) or mean differences (MDs) with 95% confidence intervals (CIs). Trial sequential analysis (TSA) assessed the sufficiency of the evidence. Risk of bias was evaluated using RoB 2, and certainty of evidence using GRADE. Five RCTs enrolled 1,267 patients, of whom 1,252 (98.8%) were included in the quantitative synthesis. Nasal mask oxygenation significantly reduced hypoxemia (RR 0.40, 95% CI 0.28 to 0.58, p < 0.0001) and severe hypoxemia (RR 0.39, 95% CI 0.22 to 0.67, p = 0.0007) compared with nasal cannula. Nasal masks also decreased the need for jaw thrust (RR 0.40, 95% CI 0.31 to 0.52) and mask-assisted ventilation (RR 0.16, 95% CI 0.05 to 0.46), while elevating minimum SpO₂ (MD 3.78, 95% CI 1.39 to 6.16). No significant differences emerged in coughing, hiccups, or PONV. Nasal mask oxygenation is associated with greater respiratory safety compared with nasal cannula oxygenation during propofol-sedated gastroscopy. This advantage manifests as reduced incidence of hypoxemia and fewer airway-related interventions, alongside a comparable overall safety profile. CRD420261291468.
- Open Access
- 22 November 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (12) , 1255
Brain Volumetric Changes Post-COVID-19: A Systematic Review
Background: The potential long-term effects of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection on the brain structure have not yet been fully elucidated. Even though existing studies have reported structural changes in the post-COVID-19 period, the results remain highly inconsistent and controversial. As such, identifying an imaging biomarker for post-COVID brains is still under investigation. This review aims to comprehensively summarize the structural MRI (sMRI) studies that focus on volumetric brain changes at least two weeks following COVID-19 infection. Methods: A systematic literature search was conducted on PubMed, SCOPUS, Web of Science, EMBASE, and Google Scholar up to 9 September 2025. Studies that utilized sMRI to assess volumetric brain changes post-COVID at greater than two weeks following infection were included. Exclusion criteria encompassed research involving pediatric or adolescent populations and imaging modalities other than sMRI. Preprints, reviews, case reports, case series and post-mortem studies were also excluded. Results: Forty-one studies satisfied the inclusion criteria and consisted of 2895 patients and 1729 healthy controls. Despite the wide variability in image acquisition protocols, data processing methods, and comorbidities between studies, multiple studies reported statistically significant volumetric reductions in the hippocampus, amygdala, thalamus, basal ganglia, nucleus accumbens and the cerebellum months to years after infection, especially in older hospitalized patients with severe COVID-19. Conclusions: The emerging literature reports long-term volume changes across various brain regions in individuals previously infected with COVID-19; however, the evidence is inconsistent. Specific imaging biomarkers following exposure to SARS-CoV-2 infection and the underlying mechanisms of these changes are yet to be identified. Future studies with harmonized imaging protocols, longitudinal designs, and integrated biomarker and clinical data are needed to define robust biomarkers and elucidate the pathophysiology of these findings.
- 22 November 2025
- Published by MDPI AG in Brain Sciences
- Vol. 15 (12) , 1255
Open AccessBrain Volumetric Changes Post-COVID-19: A Systematic Review
Background: The potential long-term effects of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV-2) infection on the brain structure have not yet been fully elucidated. Even though existing studies have reported structural changes in the post-COVID-19 period, the results remain highly inconsistent and controversial. As such, identifying an imaging biomarker for post-COVID brains is still under investigation. This review aims to comprehensively summarize the structural MRI (sMRI) studies that focus on volumetric brain changes at least two weeks following COVID-19 infection. Methods: A systematic literature search was conducted on PubMed, SCOPUS, Web of Science, EMBASE, and Google Scholar up to 9 September 2025. Studies that utilized sMRI to assess volumetric brain changes post-COVID at greater than two weeks following infection were included. Exclusion criteria encompassed research involving pediatric or adolescent populations and imaging modalities other than sMRI. Preprints, reviews, case reports, case series and post-mortem studies were also excluded. Results: Forty-one studies satisfied the inclusion criteria and consisted of 2895 patients and 1729 healthy controls. Despite the wide variability in image acquisition protocols, data processing methods, and comorbidities between studies, multiple studies reported statistically significant volumetric reductions in the hippocampus, amygdala, thalamus, basal ganglia, nucleus accumbens and the cerebellum months to years after infection, especially in older hospitalized patients with severe COVID-19. Conclusions: The emerging literature reports long-term volume changes across various brain regions in individuals previously infected with COVID-19; however, the evidence is inconsistent. Specific imaging biomarkers following exposure to SARS-CoV-2 infection and the underlying mechanisms of these changes are yet to be identified. Future studies with harmonized imaging protocols, longitudinal designs, and integrated biomarker and clinical data are needed to define robust biomarkers and elucidate the pathophysiology of these findings.